title: Proteasome Inhibitors as a Potential Cause of Heart Failure.
abstract: Proteasome inhibitors have become an important drug class in the treatment of multiple myeloma. In addition to its role in myeloma cells, the proteasome plays a critical role in the myocardium, particularly in the context of cardiac stress. The growing awareness of the cardiovascular toxicity of proteasome inhibitors is emerging following the phase 3 trials and the transition into real-world practice. This article reviews the background to this problem and the incidence of the problem in phase 3 trials and subsequent phase 2 trials in new patient cohorts and discusses the strategy to detect and manage this emerging problem.
authors.affiliation: NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London SW3 6NP, UK.
authors.forename: Georgios
authors.initials: G
authors.lastname: Koulaouzidis
authors.affiliation: NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London SW3 6NP, UK; Imperial College London, London, UK. Electronic address: a.lyon@imperial.ac.uk.
authors.forename: Alexander R
authors.initials: AR
authors.lastname: Lyon
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001896:Boron Compounds / Q000009:adverse effects / Q000627:therapeutic use; D000069286:Bortezomib / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017277:Drug Approval; D042241:Early Diagnosis; D005998:Glycine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006333:Heart Failure / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D015201:Meta-Analysis as Topic; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use; D061988:Proteasome Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001896:Boron Compounds; D009842:Oligopeptides; D061988:Proteasome Inhibitors; D000069286:Bortezomib; C548400:ixazomib; C524865:carfilzomib; D005998:Glycine
keywords: Heart failure; Multiple myeloma; Myocardium; Proteasome inhibitors